Author

Thomas Jepp

University of SurreyORCID 0000-0003-0097-8968Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetics· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:non-human primate· 2 Research Focus:drug response / drug discovery· 1 Organism:plant (other)· 1

Frequent Co-Authors

Sarah ChristianiD· 3 shared Scott V. DindotiD· 3 shared Annalise SchlaferiD· 2 shared Anne E. AndersoniD· 2 shared David Jay SegaliD· 2 shared Edwin J. WeeberiD· 2 shared Jill L. SilvermaniD· 2 shared Kevin R. NashiD· 2 shared

Activity by Year

2023-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersGenetics

Sarah ChristianORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Pharmacology & ToxicologyNucleic Acid TherapeuticsPeer-reviewedDec 3, 2025

Antisense Oligonucleotide Quantification via Splint-Ligation PCR Assay in Non-Human Primate Central Nervous System Tissues and Biofluids

Thomas Jepp, Sarah Christian, Scott V. Dindot

This paper develops a Splint-Ligation PCR assay to quantify antisense oligonucleotides in non-human primate CNS tissues and biofluids, showing high sensitivity and broad dynamic range.

2 citations

non-human primateexperimental assay

𝕏 PostBluesky

GeneticsProceedings of the National Academy of SciencesPeer-reviewedJul 21, 2025

A preclinical pig model of Angelman syndrome mirrors the early developmental trajectory of the human condition

Luke S. Myers, Sarah Christian, Sean G. Simpson…·Scott V. Dindot

This paper describes a pig model of Angelman syndrome that mirrors early developmental symptoms observed in humans.

9 citationstop 3%

plant (other)experimental assay

𝕏 PostBluesky

GeneticsScience Translational MedicinePeer-reviewedMar 22, 2023

Development of an ASO therapy for Angelman syndrome by targeting an evolutionarily conserved region at the start of the UBE3A-AS transcript

Scott V. Dindot, Sarah Christian, William J. Murphy…·Jill L. Silverman

This paper describes the development of an antisense oligonucleotide (ASO) therapy targeting the UBE3A-AS transcript to reactivate paternal UBE3A expression in Angelman syndrome models.

94 citationstop 1%

non-human primateexperimental assay

𝕏 PostBluesky